The work of Hormuzd A. Katki, Ph.D., Anil K. Chaturvedi, Ph.D., and colleagues, was recognized by the American Society of Clinical Oncology in Clinical Cancer Advances 2015: Annual Report on Progress Against Cancer. The report surveys the clinical advances of the prior year, identifying those that are expected to make the biggest impact on improving cancer prevention, treatment, and care.
They demonstrated a proof-of-principle for the effect of including an individual’s pre-screening risk of lung cancer death as part of a benefits/harms evaluation for the use of low-dose computed tomography (LDCT) screening. By targeting lung cancer screening in this way, rather than only coarse age/smoking criteria, the efficiency of LDCT screening programs could be improved, resulting in more lung cancer death prevented and fewer false positives. This work was published in the New England Journal of Medicine.